Pharmacogenomics and Endocrine Therapy in Breast Cancer

Affiliations

Editorial

Daniel F Hayes et al. J Clin Oncol. 2020.

. 2020 Feb 20;38(6):525-528.

doi: 10.1200/JCO.19.03119. Epub 2019 Dec 27.

No abstract available

Comment on

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.
He W, Grassmann F, Eriksson M, Eliasson E, Margolin S, Thorén L, Hall P, Czene K. He W, et al. J Clin Oncol. 2020 Feb 20;38(6):548-557. doi: 10.1200/JCO.19.01535. Epub 2019 Dec 4. J Clin Oncol. 2020. PMID: 31800347 Free PMC article.
CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y. Tamura K, et al. J Clin Oncol. 2020 Feb 20;38(6):558-566. doi: 10.1200/JCO.19.01412. Epub 2019 Dec 10. J Clin Oncol. 2020. PMID: 31821071 Free PMC article. Clinical Trial.